Navigation Links
Joining forces to improve lung cancer treatment
Date:4/26/2009

Lugano, 27 April 2009 Prevention, personalized therapies and closer collaborations between surgeons, medical oncologists and radiation oncologists will result in better outcomes for lung cancer patients and those at risk, a leading European expert says.

"Lung cancer is a complex disease. It is one of the most complex cancers, and the more we learn about the biology of the disease, the more we realize that improved cancer care will result from multidisciplinary treatment," said Prof Robert Pirker, from the Medical University of Vienna, Austria.

Prof Pirker is co-chair of the scientific committee of a new medical conference, the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), being held for the first time this year, 1-3 May, in Lugano, Switzerland. The conference aims to further clinical and scientific cooperation between disciplines to help in the fight against lung cancer.

Over the past 5 years, researchers have established that for patients with operable cancer, surgery followed by chemotherapy can result in good outcomes. Now, large clinical trials are beginning to evaluate that adding molecular targeted therapies can further improve the chance of a successful outcome for some patients. In addition, doctors are now attempting to refine their treatments based on the clinical characteristics of individual patients, and based on the molecular profile of their tumour.

"More sophisticated and complex treatments require more cooperation," Prof Pirker says. "That is one of the reasons why we have organized this conference. We believe the result will be better outcomes for lung cancer patients."

For patients with metastatic disease, targeted therapies have already entered clinical practice or have shown survival benefit in clinical trials. Combinations of chemotherapy and radiotherapy are also improving outcomes of loco-regional non-small-cell lung cancer. "Cure is now possible in about 15% to 20% of patients whose disease can be treated in this way," adds Prof Jean-Paul Sculier, from Institut Jules Bordet in Brussels, Belgium. Prof Sculier will chair a session on treating advanced disease at the conference.

Research groups will present new data at the meeting that reflect these developments, including:

  • A study comparing radiotherapy alone to sequential chemotherapy and radiation in locally advanced non-small-cell lung cancer, plus a correlation of gene expression level with survival (UK).
  • Promising results from a study of accelerated hypofractionated three-dimensional conformal radiotherapy (3D-CRT) with dose-per-fraction escalation for treatment of stage III non-small-cell lung cancer (Poland)
  • Confirmation that EGFR mutations (deletion in exon 19, missense L858R) are the most important predictors of sensitivity to tyrosine-kinase inhibitor targeted therapies (Italy)

Barbara Zolty from the World Health Organization (WHO) will also highlight the importance of preventing lung cancer as the first and foremost weapon against lung cancer. Ms Zolty will speak about the WHO Tobacco-Free Initiative with an enlightening keynote lecture entitled "A thousand seconds, a thousand lives."


'/>"/>

Contact: ESMO Press Office
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. New human study reinforces antioxidant benefits of tart cherries
2. Wearable Sensors Conceived at Harvard Robotics Lab Measure Hand Forces
3. VIB and Bayer join forces for plant research
4. Springer and the New York Botanical Garden Press join forces to publish botanical journals
5. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
6. Early administration of antiretroviral therapy can improve survival
7. Clemson and collaborators receive $1.1 million to improve durability of concrete infrastructure
8. Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study
9. Engineer devises ways to improve gas mileage
10. Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes
11. MacArthur Foundation awards planning grant to improve decision-making in energy policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):
(Date:5/2/2016)... ... 02, 2016 , ... Meister Media Worldwide launches its new ... added functionality give the agricultural world a taste of Meister Media Worldwide’s full ... – from precision farming via satellites and Unmanned Aerial Vehicles (UAVs) to indoor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Summit ... (NSCF) to support the development of a patient-specific stem cell therapy for the treatment ... the lab of Dr. Jeanne Loring at The Scripps Research Institute in San Diego, ...
(Date:4/28/2016)... Q BioMed Inc. (OTCQB:QBIO), ...  was featured in an article he wrote on ... To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... an essential business journal for life science executives ... Big Pharmas. Their content is designed to inform ...
Breaking Biology Technology: